PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
1 - 7 . (canceled)
8 . A pharmaceutical composition suitable for oral administration to a mammalian subject, the pharmaceutical composition comprising:
(a) from about 10 wt % to about 20 wt % solubilized testosterone ester;
(b) from about 5 wt % to about 20 wt % hydrophilic surfactant; and
(c) from about 20 wt % to about 80 wt % lipophilic surfactant,
wherein the pharmaceutical composition exhibits a percent (%) in vitro dissolution profile in phosphate buffered saline, which indicates release from the pharmaceutical composition of substantially all of the solubilized testosterone ester within about 2 hours, and
wherein administration of the pharmaceutical composition twice daily provides a serum concentration of testosterone ranging from about 300 ng/dL to about 1100 ng/dL.
9 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a liquid encased in a capsule.
10 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a semi-solid encased in a capsule.
11 . The pharmaceutical composition of claim 8 , wherein the testosterone ester is a short-chain (C 2 -C 6 ) or a medium-chain (C 7 -C 13 ) fatty acid ester.
12 . The pharmaceutical composition of claim 8 , wherein the hydrophilic surfactant exhibits a hydrophilic-lipophilic balance (HLB) of 10 to 45.
13 . The pharmaceutical composition of claim 8 , wherein the lipophilic surfactant exhibits an HLB of less than 10.
14 . The pharmaceutical composition of claim 8 , wherein the lipophilic surfactant exhibits an HLB of less than 5.
15 . The pharmaceutical composition of claim 8 , wherein the lipophilic surfactant exhibits an HLB of 1 to 2.
16 . The pharmaceutical composition of claim 8 , wherein the lipophilic surfactant is present in the pharmaceutical composition in an amount of from about 50 wt % to about 70 wt %.
17 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition further comprises a digestible oil.
18 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition further comprises an antioxidant.
19 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition further comprises one or more additional lipid-soluble therapeutic agents.
20 . The pharmaceutical composition of claim 19 , wherein the one or more additional lipid-soluble therapeutic agents is selected from a synthetic progestin, an inhibitor of type-I and/or type II 5α-reductase, finasteride, and dutasteride, or a combination thereof.
21 . The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition exhibits a percent (%) in vitro dissolution profile in phosphate buffered saline, which indicates release from the pharmaceutical composition of substantially all of the solubilized testosterone ester within about 1 hour.
22 . A method of treating a testosterone deficiency in a hypogonadal male, the method comprising administering to the hypogonadal male the pharmaceutical composition of claim 8 .